3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
5
Melanoma
4
Glioblastoma
4
Carcinoma
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms
2
Fibrolamellar hepatocellular carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Interventions
Paclitaxel
69
Bevacizumab
63
Carboplatin
53
pembrolizumab
46
olaparib
33
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
durvalumab
10
Oxaliplatin
10
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
mirvetuximab soravtansine
8
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
poly ICLC
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled